We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Icosapent ethyl for the treatment of severe hypertriglyceridemia.
- Authors
Fares, Hassan; Lavie, Carl J; DiNicolantonio, James J; O'Keefe, James H; Milani, Richard V
- Abstract
Hypertriglyceridemia is a highly prevalent lipid abnormality and it is associated with atherosclerosis, with a growing body of evidence linking elevated triglycerides (TGs) with cardiovascular disease. The current major omega-3 polyunsaturated fatty acids, eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) combination, lowers serum TGs while often increasing levels of low-density lipoprotein cholesterol. Icosapent ethyl is an omega-3 polyunsaturated fatty acid with a 96% pure ethyl ester of EPA that has been recently approved for lowering TG levels in patients with very high TGs (≥500 mg/dL), and it does so without significantly affecting serum low-density lipoprotein cholesterol. The potential benefits of omega-3 fatty acid therapy for dyslipidemias will be discussed, including the potential pros and cons of EPA alone versus the more common and readily available EPA/DHA combination therapy.
- Publication
Therapeutics & Clinical Risk Management, 2014, Vol 10, p485
- ISSN
1176-6336
- Publication type
journal article
- DOI
10.2147/TCRM.S36983